157 related articles for article (PubMed ID: 35512215)
1. PRAME Expression in Endometrioid and Serous Endometrial Carcinoma: A Potential Immunotherapeutic Target and Possible Diagnostic Pitfall.
Coppock JD; Gradecki SE; Mills AM
Int J Gynecol Pathol; 2023 Jan; 42(1):35-42. PubMed ID: 35512215
[TBL] [Abstract][Full Text] [Related]
2. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
3. IMP2 expression distinguishes endometrioid from serous endometrial adenocarcinomas.
Zhang L; Liu Y; Hao S; Woda BA; Lu D
Am J Surg Pathol; 2011 Jun; 35(6):868-72. PubMed ID: 21566514
[TBL] [Abstract][Full Text] [Related]
4. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
[TBL] [Abstract][Full Text] [Related]
5. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases.
Yemelyanova A; Ji H; Shih IeM; Wang TL; Wu LS; Ronnett BM
Am J Surg Pathol; 2009 Oct; 33(10):1504-14. PubMed ID: 19623034
[TBL] [Abstract][Full Text] [Related]
6. Expression of a novel oncofetal mRNA-binding protein IMP3 in endometrial carcinomas: diagnostic significance and clinicopathologic correlations.
Li C; Zota V; Woda BA; Rock KL; Fraire AE; Jiang Z; Lu D; Xu B; Dresser K; Lutman CV; Fischer AH
Mod Pathol; 2007 Dec; 20(12):1263-8. PubMed ID: 17885673
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
[TBL] [Abstract][Full Text] [Related]
8. Utility of α-methylacyl-coenzyme-A racemase (p504s) immunohistochemistry in distinguishing endometrial clear cell carcinomas from serous and endometrioid carcinomas.
Fadare O; Parkash V; Gwin K; Hanley KZ; Jarboe EA; Liang SX; Quick CM; Zheng W; Rawish KR; Hecht JL; Desouki MM
Hum Pathol; 2013 Dec; 44(12):2814-21. PubMed ID: 24119561
[TBL] [Abstract][Full Text] [Related]
9. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma.
Fadare O; Liang SX
Appl Immunohistochem Mol Morphol; 2012 Dec; 20(6):580-7. PubMed ID: 22495362
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
12. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
Ramalingam P; Masand RP; Euscher ED; Malpica A
Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
[TBL] [Abstract][Full Text] [Related]
13. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
Schlosshauer PW; Ellenson LH; Soslow RA
Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
[TBL] [Abstract][Full Text] [Related]
14. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors.
Kaczorowski M; Chłopek M; Kruczak A; Ryś J; Lasota J; Miettinen M
Am J Surg Pathol; 2022 Nov; 46(11):1467-1476. PubMed ID: 35973038
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of PRAME in 485 cases of epithelial tubo-ovarian tumors.
Šafanda A; Kendall Bártů M; Michálková R; Stružinská I; Drozenová J; Fabián P; Hausnerová J; Laco J; Matěj R; Škapa P; Švajdler M; Špůrková Z; Méhes G; Dundr P; Němejcová K
Virchows Arch; 2023 Oct; 483(4):509-516. PubMed ID: 37610627
[TBL] [Abstract][Full Text] [Related]
16. Serous versus high-grade endometrioid endometrial carcinoma: immunohistochemistry of RFP is not useful for differentiation.
Ussakli C; Usubutun A; Dincer N; Dolgun A; Bülbül D; Isikdogan Z; Haberal N; Ozen O; Tezel GG
Pol J Pathol; 2016; 67(3):221-227. PubMed ID: 28155970
[TBL] [Abstract][Full Text] [Related]
17. Role of WT1, B-cell lymphoma 2, Ki-67 (Mib1), and Her2/Neu as diagnostic and prognostic immunomarkers in ovarian serous and endometroid carcinoma.
Mondal SK; Basak B; Bhattacharya S; Panda UK
J Cancer Res Ther; 2021; 17(1):164-169. PubMed ID: 33723149
[TBL] [Abstract][Full Text] [Related]
18. The frequency and significance of WT-1 expression in serous endometrial carcinoma.
Hedley C; Sriraksa R; Showeil R; Van Noorden S; El-Bahrawy M
Hum Pathol; 2014 Sep; 45(9):1879-84. PubMed ID: 25033726
[TBL] [Abstract][Full Text] [Related]
19. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases.
Darvishian F; Hummer AJ; Thaler HT; Bhargava R; Linkov I; Asher M; Soslow RA
Am J Surg Pathol; 2004 Dec; 28(12):1568-78. PubMed ID: 15577675
[TBL] [Abstract][Full Text] [Related]
20. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]